阿利西尤单抗联合阿托伐他汀治疗冠心病合并高脂血症的效果  

Aliciumumab in Combination with Atorvastatin in the Treatment of Coronary Heart Disease with Hyperlipidemia

作　　者：陈亮 CHEN Liang(Fujian Sanming City Shaxian District General Hospital,Sanming 365050,China)

机构地区：[1]福建省三明市沙县区总医院,福建三明365050

出　　处：《中国医药指南》2023年第35期31-33,共3页Guide of China Medicine

摘　　要：目的分析阿利西尤单抗联合阿托伐他汀治疗冠心病(CHD)合并高脂血症的临床效果。方法选择福建省三明市沙县区总医院在2020年10月至2022年10月内收治的冠心病合并高脂血症患者98例,按照入院前后的顺序划分,先入院的49例实施阿托伐他汀治疗为对照组,后入院的49例增加阿利西尤单抗注射为观察组;比较两组治疗前后血脂指标、相关生化指标。结果两组各自治疗后的血脂指标以及生化指标相较治疗前均有改善。但治疗后两组互相对比,观察组高密度脂蛋白胆固醇(HDL-C)水平更高,甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)更低(P<0.05)。两组各自治疗后的生化指标相较治疗前均有改善。但治疗后两组互相对比,观察组高敏C反应蛋白(hs-CRP)、肿瘤坏死因子α(TNF-α)、血清氨基末端脑钠尿肽前体(NT-proBNP)水平低于对照组(P<0.05)。结论在冠心病合并高脂血症中口服阿托伐他汀再联合阿利西尤单抗注射,能够有效改善患者血脂水平,降低s-CRP、TNF-α、NT-proBNP水平,加快患者康复。Objective To analyze the clinical efficacy of Allisy combined with Atorvastatin in the treatment of coronary heart disease(CHD)with hyperlipidemia.Methods A total of 98 patients with coronary heart disease complicated with hyperlipidemia were selected from the Sha County General Hospital of Sanming,Fujian province from October 2020 to October 2022,according to the order before and after admission,49 cases were treated with Atorvastatin as control group,and the other 49 cases were treated with aliciumumab as observation group The blood lipid indexes and related biochemical indexes were compared between the two groups before and after treatment.Results Both groups showed improvement in their respective post-treatment lipid indices as well as biochemical indices compared to pre-treatment.However,when the two groups were compared with each other after treatment,the observation group had a higher level of HDL-C,higher levels of triacylglycerol(TG),LDL-C,total cholesterol(TC)(P<0.05).The biochemical indices of the two groups after their respective treatments compared to the before,all of them improved.However,comparing the two groups after treatment,the levels of high-sensitivity C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α),serum aminoterminal brain natriuretic peptide precursor(NT-proBNP)were lower than those of the control group(P<0.05).Conclusions Oral administration of Atorvastatin combined with aliciumumab in patients with coronary heart disease and hyperlipidemia can effectively improve the level of blood lipids,reduce the levels of hs-CRP,TNF-αand NT-proBNP,the rehabilitation of patients are worth promoting.

关 键 词：冠心病 高脂血症 阿利西尤单抗 阿托伐他汀 

分 类 号：R541.4[医药卫生—心血管疾病]